All data are based on the daily closing price as of September 6, 2024
a
ABL Bio
298380.KQ
21.75 USD
1.12
+5.43%
Overview
Last close
21.75 usd
Market cap
1.05B usd
52 week high
25.93 usd
52 week low
11.47 usd
Target price
27.17 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
42.1362
Price/Book Value
26.123
Enterprise Value
1.05B usd
EV/Revenue
42.4081
EV/EBITDA
-32.1061
Key financials
Revenue TTM
24.64M usd
Gross Profit TTM
50.26M usd
EBITDA TTM
-28.73M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
120.71B usd
Net debt
42.00B usd
About
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea.